Amplio Pharma B.V. is a female-founded pharmaceutical startup with the ambition to develop innovative, patent protected drug products of cornerstone drug substances. Our first, patent-protected, candidate drug product is NovoBioJect, the future 1st line treatment choice for autoimmune diseases like rheumatoid arthritis (RA).
The management team consists of the three founders Marguerite Mensonides (CEO), Karin von Wachenfeldt (Chief Scientific Officer Clinical), and Charlott Brunmark (Chief Scientific Officer Non-Clinical) and Curtis Sprouse (Chief Strategy Officer; USA-based). The team is supported by both a strategic advisory board with European and USA industry veterans and by a scientific advisory board with KOLs from the Netherlands and the USA.
We have secured a qualified Seed Round of 1.05M EUR from Dutch investors at a pre-money valuation of 7.5M EUR and PPS of 55 EUR. This capital will be used to reach our next milestone, NovoBioJect proof-of-principle in RA patients (a Phase 1b trial). We are looking for additional investment within this Seed Round of max 500K EUR (to be secured prior to enrolling the first patient in the planned clinical trial).
Following this Seed Round, we will be looking to secure a Series A round of ca. 5M EUR to reach our final milestone of proof-of-concept in RA patients prior to exit: a M&A by the pharma industry. Total capital need (Seed + SeriesA) of ca. 6.5M EUR; expected value at exit (comparables) of >150M EUR.
